SCHEMBL13765048

SCHEMBL13765048

CCc1ccc2oc(N3C(=O)CCC3=O)nc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 7/20 0.46
▸ RAB9A P51151 6/20 0.46
▸ MAPT P10636 6/20 0.46
▸ MEN1 O00255 6/20 0.46
▸ ALDH1A1 P00352 6/20 0.46
▸ KMT2A Q03164 6/20 0.46
▸ KDM4E B2RXH2 6/20 0.46
▸ TP53 P04637 6/20 0.46
▸ NPC1 O15118 5/20 0.46
▸ HPGD P15428 4/20 0.46
▸ HSD17B10 Q99714 4/20 0.46
▸ NFKB1 P19838 1/20 0.46
▸ NFKB2 Q00653 1/20 0.46
▸ RELA Q04206 1/20 0.46
▸ GAA P10253 3/20 0.43
▸ POLB P06746 1/20 0.43
▸ CASP3 P42574 1/20 0.43
▸ SENP8 Q96LD8 1/20 0.43
▸ SENP7 Q9BQF6 1/20 0.43
▸ SENP6 Q9GZR1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5476977 0.86 GABRP (0.39) SMN1; SMN2MEN1ALDH1A1KMT2AKDM4E
SCHEMBL5479018 0.82 GABRP (0.51) SMN1; SMN2RAB9AMAPTMEN1ALDH1A1
SCHEMBL13486453 0.76 MEN1 (0.44) SMN1; SMN2MAPTMEN1ALDH1A1KMT2A
SCHEMBL13486503 0.71 MAPT (0.45) SMN1; SMN2RAB9AMAPTMEN1ALDH1A1
SCHEMBL8180377 0.71 RAB9A (0.56) SMN1; SMN2RAB9AMAPTMEN1ALDH1A1
SCHEMBL10224642 0.71 GAA (0.69) SMN1; SMN2RAB9AMAPTMEN1ALDH1A1
SCHEMBL11324885 0.69 GAA (0.59) SMN1; SMN2RAB9AMAPTMEN1ALDH1A1
SCHEMBL240344 0.69 RAB9A (0.63) SMN1; SMN2RAB9AMAPTMEN1ALDH1A1
SCHEMBL14225537 0.69 MAPT (0.59) SMN1; SMN2RAB9AMAPTMEN1ALDH1A1
SCHEMBL6739644 0.69 MAPT (0.56) SMN1; SMN2RAB9AMAPTMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7563877-B2 Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 ENANTA PHARMACEUTICALS, INC. (US) 2009-07-21 — — US disclosed
US-20070207972-A1 Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 ENANTA PHARMACEUTICALS, INC. 2007-09-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070207972-A1 Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 DHPS, TET1, TET2 SMN1; SMN2 3647/4885RAB9A 2521/4885MAPT 4438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback